Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Keryx Biopharmaceuticals
So what: Keryx licensed the rights to colorectal cancer treatment perifosine from Aeterna Zentaris
Now what: Investors are celebrating today because each incremental step forward in the drug-development process brings a small, money-losing company like Keryx one step closer to being a successful, profitable company. That said, we all know about counting chickens before they hatch, so Keryx investors may not want to let their excitement get too out of control quite yet.
Want to keep up to date on these stocks?